• Home
  • About
  • Contact
MARINNOVAC Limited
  • Home
  • About
  • Contact
Picture
Picture

Our Story

MARINNOVAC is an R&D amplifier platform for products, services and tool development to solve global aquaculture industry health management issues. MARINNOVAC is an open, inclusive, collaborative platform / cluster of visionary SMEs and researchers focused on aquatic animal health R&D teams.
​​
MARINNOVAC was created through a continuous process of building selective project and/or market focused strategic alliances based on an ethic of  IP and margin sharing between partners.  MARINNOVAC is pursuing a collaboration policy based on mutual trust, respect and transparency between its partners, strategic allies and the global aquaculture industry. 

Our Founders

Picture

Susan
​Didlick

Manager of Jas Biologicals and MARINNOVAC UK Limited and MARINNOVAC Limited Director.
Sue leads the MARINNOVAC UK Limited virology team with expertise that include: viral vaccine technologies, cell technology, antibody production, virology techniques and PCR diagnostics.
Sue is Manager of JAS Biologicals Limited that was established in 2004
and MARINNOVAC UK Limited established in 2019 to provide
early stage contract services
for autogenous and experimental vaccine development and registration.
Sue is also leading the AQUANOSIS diagnostic services by Marinnovac UK Ltd.
Picture

Patrick
Smith

​Director of Tethys Aquaculture limited and MARINNOVAC Limited Director.
​He was Global Director of New Business Development / Discovery for Intervet-Schering Plough Animal Health.
Patrick has over forty years of
experience in the field of fish vaccines
and fish immunology working in research and SME and large Pharma. He almost single handed developed the testing and regulatory affairs process for fish vaccines alongside the UK Veterinary Medicines Directorate.  Patrick is Vice-President of the European Association
of Fish Pathologists, Director of the Vet FishMed Alliance, Scientific advisor to the European Medicines Agency (recently advising on the first plasmid vaccine (DNA Vaccine) for fish. 
Picture

Ansgar
​Stratmann

​​   Ansgar is Gesch.ftsführer/CEO of
    W42 GmbH and Director of    
    MARINNOVAC Limited. Ansgar has
    developed the W42 Pichia expression    
    system that is based on methanol  
    (explosion proven) or glycerol
    at de-repressing feeds and induces
    enzyme expression and easy down-
    streaming.
    The W42 Pichia expression platform
    is utilised for the production of selected    
    sequences from virus capsids allowing
    the production of viral VLP vaccines for
    the major viral diseases of aquatic
    animals.  Ansgar leads the
    Biotechnology  team of ​Marinnovac
​    Limited.
Picture

Panos Christofilogiannis

​Managing Director of AQUARK, Director of MARINNOVAC Limited. Panos is fish health expert with deep knowledge and 23-year experience on applied research and technology transfer in European aquaculture industry.
​He holds a degree in veterinary science, a M.Sc. in Applied Fish Biology, a M.Sc. in Aquatic Veterinary Studies and a Ph.D. in the use of antibiotics in aquaculture.  
Panos has worked as the Head Fish Pathologist on three fish farm units.
He has acted as technical advisor to a number of organisations including the Federation of Greek Maricultures, the FAO, the Federation of European Aquaculture Producers and others. Panos is the business development manager of Marinnovac Limited.
JAS BIOLOGICALS Ltd
MARINNOVAC UK Ltd


JAS was established 2004 in Cambridge UK as a vaccine development company providing contract services to animal health care companies. In 2011entered into a joint venture partnership with a contract manufacturing company Biosynergy (Europe) Limited. www.biosynergyeurope.com.
We have highly trained staff with over 20 years of experience in the vaccine and biotechnology field. We have proven ability to produce novel and conventional viral vaccines for several international veterinary pharmaceutical companies. Our aim is to provide early stage contract services for vaccine development and registration. We have extensive experience in the production of seed stocks and the optimization of cell lines and reagents as well as in the production and purification of proteins and monoclonal antibodies. JAS has facilities for both mammalian and microbial cell culture and comprehensive bank of mammalian cell lines and virus stocks.

TETHYS AQUACULTURE Ltd

​
TETHYS AQUACULTURE Limited has been established in UK to provide a bridge between academic research and industry to facilitate and increase the impact of excellent research which, in many cases, is not yet realizing its full industrial potential. TETHYS AQUACULTURE Limited vision is to become:“Leaders in amplifying research impact in Aquatic Animal Health through knowledge and experience”.  TETHYS AQUACULTURE Limited is focused on generating impact from Aquatic Animal Health Research in order to support the fish farming industry to have access to innovative solutions and technologies to prevent fish diseases which are a major limiting factor for the sustainability of Aquaculture Industry. TETHYS AQUACULTURE Limited team has a unique blend of academic research experience and industrial experience placing them in a perfect position to act as a bridge between the two. The input provided can enhance the impact of basic research and speed-up the application of research and the transfer of results into commercial production avoiding unnecessary delays and thus providing the applied aquatic animal health solutions.
W42 Industrial Biotechnology GmbH

​W42 is partner of an international consortium comprising different European companies covering all areas of modern fish-industry and health management. Our experts are focused on the development and use of ‘traditional’ high-efficient vaccines that are produced individually for our customers, based on their specific needs. Furthermore development of different recombinant vaccines using the powerful expression platform Pichia pastoris are actually running with great success. First trials by immunization and challenge experiments demonstrate the power of our technology. Basically we offer the development and production of customer specific vaccines (GMO and non-GMO) based on the analysis of samples directly from the individual fish-farm. By this unique service we can support our customers individually to run modern aquaculture with maximal outcome.
AQUARK

​
AQUARK is a leading innovation amplifier and technology transfer organisation specialising in Aquaculture. With close relationships with the fish farmer associations in the main Mediterranean fish producing countries, AQUARK has the capacity and expertise to anticipate Mediterranean aquaculture industry needs and deliver solutions. We are involved in a range of EU funded research (PERFORMFISH, PARAFISHCONTROL, TARGETFISH) and training projects (INTRANEMMA); AQUARK has strong commitment to collaborative approaches and is acting as an ambassador of new applied concept techniques, technologies, services and products from the research community to the fish farming community. Active within Leonardo da Vinci Projects Vocational Aqualabs, and Pescalex, AQUARK provided the core concept development of the mentorship approach and provided the industry inputs into the “Aquaculture Talent Hatchery” course on entrepreneurship and led the Aquaculture Node in Columbus EU project. 
  • Home
  • About
  • Contact